SCOPUS 정보 검색 플랫폼

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 543-551

The practical application of adaptive study design in early phase clinical trials: A retrospective analysis of time savings

(6) Lorch, U a Berelowitz, K a Ozen, C a Naseem, A a Akuffo, E a Taubel, J a

a ST GEORGE'S UNIVERSITY OF LONDON (United Kingdom)

Author keywords

Adaptive study design; Clinical trials; Early phase; Protocol; Protocol amendments; Time savings

Indexed keywords

ADAPTIVE STUDY DESIGN; ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; STUDY DESIGN; TIME; UNITED KINGDOM;

CLINICAL TRIALS, PHASE I AS TOPIC; COST SAVINGS; DECISION MAKING, ORGANIZATIONAL; DRUGS, INVESTIGATIONAL; HUMANS; LONDON; PROGRAM EVALUATION; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84864278404 PISSN: 00316970 EISSN: 14321041 Source Type: Journal
DOI: 10.1007/s00228-011-1176-3 Document Type: Article

Times cited : (14)

References (9)

1
- 33646245937
- Adaptive designs in clinical drug development - An executive summary of the PhRMA working group
- Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J (2006) Adaptive designs in clinical drug development - an executive summary of the PhRMA working group. J Biopharm Stat 16:275-283. http://www.gemini-grp.com/ Bayes/PhRMA.pdf
- (2006) J Biopharm Stat , vol.16 , pp. 275-283
- Gallo, P.¹ Chuang-Stein, C.² Dragalin, V.³ Gaydos, B.⁴ Krams, M.⁵ Pinheiro, J.⁶

2
- 36849035490
- Translation of innovative designs into phase I trials
- DOI 10.1200/JCO.2007.12.1012
- Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A (2007) Translation of innovative designs into phase 1 trials. J Clin Oncol 25:4982-4986 (Pubitemid 350220431)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.31 , pp. 4982-4986
- Rogatko, A.¹ Schoeneck, D.² Jonas, W.³ Tighiouart, M.⁴ Khuri, F.R.⁵ Porter, A.⁶

3
- 50549174560
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
- Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353
- (1961) J Chronic Dis , vol.13 , pp. 346-353
- Gehan, E.A.¹

4
- 70449645866
- CHMP/EWP/2459/02
- EMA Committee for Medicinal Products for Human Use (2007) Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. CHMP/EWP/2459/02. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003616.pdf
- (2007) Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design

5
- 84864281369
- EMA/779520/2009
- EMA (2009) EMA/EFPIA 2nd workshop, adaptive design in confirmatory trials. EMA/779520/2009. http://www.ema.europa.eu/docs/en-GB/document-library/ Minutes/2010/04/WC500089206.pdf
- (2009) EMA/EFPIA 2nd Workshop, Adaptive Design in Confirmatory Trials

6
- 77954875817
- FDA (2010) Guidance for industry; adaptive design clinical trials for drugs and biologics. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm201790.pdf
- (2010) Guidance for Industry; Adaptive Design Clinical Trials for Drugs and Biologics

7
- 84864287983
- Adaptive designs in early development; oral presentation
- June 2011, Budapest
- De Ridder F (2011) Adaptive designs in early development; oral presentation. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, June 2011, Budapest
- (2011) 10th Congress of the European Association for Clinical Pharmacology and Therapeutics
- De Ridder, F.¹

8
- 84864279439
- Communication from the commission - Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial
- European Commission
- European Commission (2010) Communication from the commission - detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial. OJC 82:1-19
- (2010) OJC , vol.82 , pp. 1-19

9
- 84864284134
- The MHRA website: amendments to your clinical trial authorisation: additional information. http://www.mhra.gov.uk/Howweregulate/Medicines/ Licensingofmedicines/Clinicaltrials/ManagingyourCTA/Amendments/ Additionalinformation/index.htm
- The MHRA Website: Amendments to Your Clinical Trial Authorisation: Additional Information

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.